Is There is a Role of Prophylactic Therapy With Tamsulosin Before Extracorporeal Shock Wave Lithotripsy to Avoid Development of Steinstrasse ?
Information source: HaEmek Medical Center, Israel
Information obtained from ClinicalTrials.gov on October 19, 2009
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Kidney Stones
Intervention: tamsulosin 0.4mg (Drug)
Phase: N/A
Status: Recruiting
Sponsored by: HaEmek Medical Center, Israel Official(s) and/or principal investigator(s):
doron perez, Principal Investigator, Affiliation: Urology department: Haemek Medical Center
Overall contact:
DORON PEREZ, M.D., Phone: +972-4-6495115, Email: perez_do@clalit.org.il
Summary
The purpose of this study is to determine if there is a role of prophylactic therapy with
tamsulosin prior extracorporeal shock wave lithotripsy to avoid development of steinstrasse.
150 persons that will go to Extracorporeal shock wave lithotripsy will randomize to 2
groups.
Group 1 - of 75 persons will recieve tamsulosin 0. 4 mg x 1/d 2 days before the lithotripsy .
Group 2 - of 75 persons will not recieve tamsulosin. 48 hour after the ESWL all 2 group will
take abdominal radiograph to evaluate the presence of steinstrasse.
Clinical Details
Study design: Screening, Longitudinal, Defined Population, Prospective Study
Eligibility
Minimum age: 15 Years.
Maximum age: 85 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- size of stone 1-2 cm
Exclusion Criteria:
- ureteral stricture Presence of internal stent prior use of alfa bloker prior ESWL
Locations and Contacts
DORON PEREZ, M.D., Phone: +972-4-6495115, Email: perez_do@clalit.org.il
Haemek medical center, afula 18100, Israel; Recruiting
DORON PEREZ, M.D., Phone: +972-4-6495115, Email: perez_do@clalit.org.il
doron perez, M.D., Principal Investigator
Additional Information
Starting date: May 2007
Last updated: June 20, 2007
|
